Cheese that is aged or strongly fermented (e.g., blue cheese, cheddar) contains high levels of tyramine, which can precipitate a hypertensive crisis when combined with higher doses of selegiline. While the 5 mg dose carries a lower risk, it is prudent to limit intake of such foods or follow a low-tyramine diet as advised by your clinician.
Standard workplace or sports drug screens typically test for substances of abuse, not prescription MAO-B inhibitors. However, specific testing protocols vary; if you are subject to a detailed pharmacological panel, disclose your medication to the testing authority in advance.
Many decongestants contain phenylephrine or pseudoephedrine, which are sympathomimetic agents. When taken with selegiline, they can increase blood pressure. Choose non-sympathomimetic alternatives (e.g., saline nasal spray) and consult a pharmacist before using any OTC product.
Eldepryl tablets typically bear an imprint indicating the manufacturer and dosage strength (e.g., “EL 5” for 5 mg). The specific code helps pharmacists verify authenticity and differentiate strengths.
Yes, but carry the medication in its original packaging with a copy of the prescription. Some countries require a doctor’s letter for controlled or prescription-only medicines; check the destination’s import regulations before travel.
St. John’s wort is a serotonergic herb and can increase the risk of serotonin syndrome when combined with selegiline. Patients should avoid this supplement unless a healthcare professional explicitly approves its use.
Provided the bottle is kept tightly closed and stored at room temperature away from moisture, the tablets remain stable until the printed expiry date. Do not use tablets past that date.
Yes, selegiline is also marketed as a generic product. The active ingredient, dosage, and formulation are identical; the generic version may be prescribed for cost considerations.
If you remember the missed dose within a few hours, you may take it. If it is close to the time of your next scheduled dose, skip the missed tablet and continue with your regular dosing schedule. Do not double the dose to “catch up.”
Because selegiline can affect blood pressure and interact with anesthetic agents, it is standard practice to inform the surgical team of all medications. Your anesthetist may advise temporary discontinuation; follow their specific guidance.
Eldepryl is a prescription medication that contains the active ingredient selegiline. It belongs to the neurology therapeutic area and is classified as a selective monoamine-oxidase B (MAO-B) inhibitor. Eldepryl is supplied as a pill in two strengths: 5 mg and 10 mg. In the United Kingdom it is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available only with a prescription from a qualified prescriber. The product is marketed by Novartis.
Selegiline inhibits the enzyme monoamine-oxidase B, which is responsible for breaking down dopamine in the brain. By reducing this enzymatic activity, Eldepryl raises the levels of dopamine available for neuronal signaling. The increase in dopamine helps to compensate for the loss of dopaminergic neurons that occurs in Parkinson’s disease, thereby improving motor control.
Key pharmacological points:
Eldepryl is approved by the MHRA for use as an adjunct therapy in people with Parkinson’s disease who are already receiving levodopa. It is prescribed to:
The medication is intended for adult patients with a confirmed diagnosis of Parkinson’s disease.
Some clinical investigations have explored selegiline for conditions other than Parkinson’s disease. Notably:
Off-label use of Eldepryl must be guided by a qualified healthcare professional and is not endorsed by regulatory agencies.
Patients should disclose all current medications, supplements, and medical conditions before starting Eldepryl.
These effects are usually mild and may diminish with continued therapy.
If any of these serious symptoms occur, seek immediate medical attention.
Mechanistically, many interactions involve the cytochrome P450 system (particularly CYP2B6) or additive effects on monoamine pathways.
When specific interaction data are unavailable, patients should inform their pharmacist or prescriber of all concomitant substances.
Note: Dosing must be individualized; the information above reflects the approved strengths of 5 mg and 10 mg tablets.
Patients should maintain scheduled appointments with their neurologist or prescribing clinician.
This article provides educational information about Eldepryl and is not a substitute for professional medical advice. Treatment decisions, including the use of medications for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
